Peer-reviewed veterinary case report
Survivin protein levels in untreated and relapsed dog lymphoma tumors
By Rebhun, R.B. et al.·Published in Journal of Veterinary Internal Medicine·2008·Colorado State University Departments of Clinical Sciences, and Microbiology, Immunology and Pathology, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, , Fort Collins, CO, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative Analysis of Survivin Expression in Untreated and Relapsed Canine Lymphoma
- Species:
- dog
Plain-English summary
A group of 31 dogs with advanced lymphoma (a type of cancer) were studied to see how a protein called survivin affected their treatment outcomes. The dogs that had high levels of survivin before starting chemotherapy had a shorter time without disease progression compared to those with lower levels. Specifically, dogs with high survivin levels had an average of 171 days before their cancer worsened, while those with low levels lasted about 321 days. This suggests that high survivin levels could indicate a higher risk of treatment failure in dogs with this type of lymphoma.
People also search for: dog lymphoma treatment · survivin protein in dogs · canine cancer prognosis · chemotherapy for dog lymphoma · signs of dog cancer relapse
Abstract
Abstract Background Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1939-1676.2008.0143.x